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Introduction: The Multidimensional Fatigue Inventory (MFI) is commonly used in patients with Parkin-
son’s disease (PD). However, most measurement properties have not been investigated in this pop-
ulation. The aim of this study was to investigate internal consistency, test-retest reliability, measurement
error, structural validity, and ﬂoor and ceiling effects of the MFI in PD.
Methods: Patients with PD (N ¼ 153) completed the MFI at baseline and week 3 in a randomized clinical
trial. Cronbach’s a, intraclass correlation coefﬁcient (ICC), and the smallest detectable change (SDC) were
calculated. Bland and Altman analysis was performed. Principal Component Analysis (PCA) was used to
explore structural validity. Floor and ceiling effects were investigated.
Results: Cronbach’s a for the MFI-total and subscales ranged from 0.74 (reduced motivation (RM)) to 0.92
(MFI-total). ICC’s ranged from 0.65 (mental fatigue (MF) to 0.81 (physical fatigue (PF)), SDC ranged from 4
points (PF and RM) to 15 points (MFI-total). Bland and Altman analysis showed no systematic differences
between assessments. A ﬂoor effect was found for MF and ceiling effects for PF and reduced activity (RA).
A four-factor model was extracted, combining general fatigue (GF) and PF as one factor.
Conclusions: The MFI is reliable and valid to assess fatigue in patients with PD. Clinicians and researchers
interested in assessing speciﬁc aspects of fatigue should consider interpreting GF and PF as one subscale
measuring physical aspects of fatigue. To establish whether the MFI can detect meaningful changes,
studies on anchor-based responsiveness and the minimal important change are needed in PD.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Fatigue is common in patients with idiopathic Parkinson’s
disease (PD) and has a negative impact on health-related quality of
life (HRQOL) [1e3]. Prevalence rates reported in the literature range
from 32% to 50% [4,5]. One of the challenges in assessing fatigue is
the lack of a widely accepted deﬁnition [6] and with that, differ-
entiating its many dimensions [7,8]. Fatigue usually refers to the
difﬁculty initiating or sustaining voluntary activities [9]. Its multi-
dimensionality is believed to result from a complex interplay
between the underlying disease process, peripheral control
systems (i.e. muscle fatigability), central control systems (i.e.
subjective sense of fatigue) and environmental factors [9]. This
complexity may be reﬂected in the large number of self-report
questionnaires that are currently available to measure fatigue asences Leiden, Department of
AJ Leiden, The Netherlands
lsevier OA license.either a multidimensional or an unidimensional assessment in
patients with PD.
A commonly used instrument to assess the multidimensional
aspects of fatigue in patients with PD is the Multidimensional
Fatigue Inventory (MFI) [8]. The MFI is a self-report questionnaire
that assesses ﬁve dimensions of fatigue (i.e. general fatigue (GF),
physical fatigue (PF), reduced activity (RA), mental fatigue (MF)
and reduced motivation (RM)). Recently, the Movement Disor-
ders Society Task Force on Rating Scales for Parkinson’s disease
suggested the MFI as a screening instrument for fatigue and
recommended the MFI for the assessment of fatigue severity in
patients with PD [10]. Unfortunately, these recommendations
were largely based on evidence derived from studies in non-PD
samples. In addition, measurement properties such as internal
consistency, test-retest reliability, measurement error, structural
validity and responsiveness have not been investigated in
patients with PD [11].
The aim of the present study was therefore to investigate the
internal consistency, test-retest reliability, measurement error,
structural validity and ﬂoor and ceiling effects of theMFI in patients
with PD.
Table 1
Patient characteristics at baseline.
Total sample (N ¼ 153)a Late intervention (N ¼ 77)a
Demography
Male/femaleb 88/65 38/39
Age (years) 67.06 (7.54) 67.38 (8.11)
Language Dutch/Englishb 105/48 53/24
PD characteristics
Disease duration (years) 8.25 (5.09) 8.63 (5.55)
H&Y (on) 2.78 (0.60) 2.82 (0.64)
H&Y II/III/IV (on)b 71/64/18 33/33/11
Clinical data
UPDRS total (on) 56.03 (16.01) 55.29 (15.71)
UPDRS I (on) 3.30 (1.72) 3.08 (1.71)
UPDRS II (on) 16.42 (6.03) 16.36 (5.95)
UPDRS III (on) 33.05 (11.28) 32.81 (11.06)
UPDRS IV (on) 3.34 (3.26) 3.22 (3.39)
MFI-total 62.74 (17.94) 62.69 (19.23)
MFI general fatigue 13.83 (4.30) 14.19 (4.34)
MFI physical fatigue 13.93 (4.51) 14.23 (4.80)
MFI reduced activity 13.45 (4.98) 13.00 (5.36)
MFI mental fatigue 10.36 (4.68) 10.38 (4.76)
MFI reduced motivation 11.16 (4.30) 10.88 (4.69)
HADS anxiety 6.90 (3.91) 6.82 (4.00)
HADS depression 7.20 (3.50) 7.09 (3.78)
HADS anxiety, Hospital Anxiety and Depression Scale anxiety subscale; HADS
depression, Hospital Anxiety and Depression Scale depression subscale; H&Y (on),
Hoehn and Yahr stages during on; MFI, Multidimensional Fatigue Inventory; PD,
Parkinson’s disease; SD, Standard deviation; UPDRS total, I, II, III, IV (on), Uniﬁed
Parkinson’s Disease Rating Scale total score, part I, II, III and IV during on.
a Expressed as mean (SD).
b Expressed as number of patients.
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2.1. Population and design
This study was part of a randomized clinical trial (the ‘Rescue’ trial (Rehabili-
tation in Parkinson’s Disease: Strategies for Cueing) QLK6-CT-2001-00120) about
the effects of cueing training on gait and gait-related activity in patients with PD
[12]. In this study, 153 patients with PD were recruited from three centers: North-
umbria University, Newcastle upon Tyne (UK); Katholieke Universiteit Leuven,
Leuven (Belgium) and the VU University Medical Center, Amsterdam (The
Netherlands). The study was approved by the ethics committee of each centre. All
patients gave written informed consent. Patients were randomly allocated to an
early or late intervention group by an independent person, not involved in the study.
Further details about design and outcomes of the study have been published
previously [12].
2.2. Subjects
Patients were recruited according to the following criteria: 1) age 18e80; 2)
diagnosis of PD, deﬁned by the UK Brain Bank Criteria [13]; 3) Hoehn and Yahr (H&Y)
stage IIeIV [14]; 4) stable drug usage and 5) mild to severe gait disturbance (score
>1 on the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) item 29) [15]. Patients
were excluded if they had: 1) undergone deep brain stimulation or other stereotactic
neurosurgery; 2) cognitive impairment (Mini Mental State Examination
(MMSE) <24) [16]; 3) disorders interfering with participation in cueing training,
including neurological (stroke, multiple sclerosis, brain tumor), cardiopulmonary
(chronic obstructive disorders, angina pectoris) and orthopedic (osteoarthritis,
rheumatoid arthritis and back pain) conditions; 4) unpredictable and long lasting off
periods (score 1 on item 37 and score >2 on item 39 of the UPDRS) [15] or 5) had
participated in a physiotherapy program two months before starting the trial.
2.3. The Multidimensional Fatigue Inventory
The Multidimensional Fatigue Inventory was originally developed and validated
in the Dutch language in patients with cancer and patients with chronic fatigue
syndrome [8] and was translated and validated in English in patients with cancer
[17]. The MFI is a self-report questionnaire that assesses the impact of fatigue and
comprises ﬁve dimensions (GF, PF, RA, MF and RM). Each subscale contains four
items, with two items formulated in a positive (e.g. I feel ﬁt) and two formulated in
a negative direction (e.g. I feel fatigued). The addressed recall period is ‘lately’. All
items are scored on a ﬁve-point Likert scale ranging from 1 (yes, that is true) to 5 (no,
that is not true). The negative formulated items must be recoded before adding up
scores. The obtainable score within each subscale ranges from 4 (absence of fatigue)
to 20 (maximum fatigue).
2.4. Procedure
Patients completed the MFI at baseline (t1) and week 3 (t2), during visits from
a trained observer blinded to treatment allocation and not involved in data analysis.
Both assessments were performed in the patients’ homes at the same time of the day
in the on phase, approximately 1 h after medication intake.
2.5. Statistical analysis
All data were analyzed with PASW statistical package (PASW Statistics version
18.0, IBM Corp., New York, USA). The mean scores of the MFI-total and subscales
were investigated for statistically signiﬁcant differences between Dutch and English
speaking patients. Dependent on distribution by visual plot, parametric or non-
parametric analyses were applied. A two-tailed signiﬁcance level of 0.05 was used
for all tests.
2.5.1. Reliability
Internal consistency is the degree of the interrelatedness among items,
assuming the questionnaire to be unidimensional [18]. Cronbach’s a was calculated
for the total scale and for all subscales separately at t1 (N ¼ 153) and considered
adequate if it ranged from 0.70 to 0.95 [19].
Reliability was deﬁned as the proportion of the total variance in the measure-
ments due to ‘true’ differences between patients [18]. To ensure that patients were
stable in the period between two assessments (i.e. no intervention was applied),
only data from the late intervention group (N ¼ 77) at t1 and t2 were used for
analyses. For test-retest reliability, the intraclass correlation coefﬁcient (ICC) was
calculated. A two-way mixed effects model with an absolute agreement deﬁnition
was used, assuming that included patients are a random selection of the population
and the raters (i.e. items) are ﬁxed. The ICC was considered adequate if 0.70 [19].
Measurement error, deﬁned as the systematic and random error of a score that
is not attributed to true changes in the construct to be measured [18], was
determined with the Bland and Altman method [20]. The limits of agreement were
calculated as the mean difference between two consecutive assessments
 1.96  standard deviation (SD) of this difference. In addition, the smallestdetectable change (SDC) was calculated, based on the standard error of measure-
ment (SEM). The SDC was calculated by 1.96  O2  SEM, where the SEM was
computed by SD  O(1ICC) [21].
2.5.2. Structural validity
Structural validity, deﬁned as the degree to which scores of a questionnaire are
an adequate reﬂection of the dimensionality of the construct to be measured [18],
was investigated by means of exploratory factor analysis. A Principal Component
Analysis (PCA) was used to extract factors. As correlations between factors were
expected, the obtained factors were rotated oblique using the direct oblimin
procedure. A minimum eigenvalue of 1 was speciﬁed as extraction criterion and the
criterion for factor loading was set at0.40. The existing names of the MFI subscales
[8] were used to label the extracted factors. Data from t1 were used for analysis
(N ¼ 153).
2.5.3. Floor and ceiling effects
A ﬂoor or ceiling effect was present if more than 15% of patients achieved the
lowest or highest possible score on a questionnaire [19]. Data from t1 were used for
analysis (N ¼ 153).3. Results
Table 1 presents the characteristics of the total sample (N¼ 153)
and of the late intervention group subsample (N ¼ 77). One
hundred and ﬁve patients completed the Dutch language version
and 48 patients completed the English language version of the MFI.
No statistically signiﬁcant differences in fatigue scores were found
between Dutch and English speaking patients. The mean level of
fatigue (MFI-total) was 62.74 (SD ¼ 17.94). Most patients had mild-
to-moderate disease severity as 46% (N ¼ 71) of patients were in
H&Y stage II, 42% (N ¼ 64) in stage III, and 12% (N ¼ 18) in stage IV.
There were no item responses missing and all data were nor-
mally distributed by visual plot.3.1. Reliability
Table 2 presents the results for internal consistency, test-retest
reliability and measurement error. The MFI-total and all subscales
Table 2
Reliability and measurement error.
Reliability Measurement error
Internal consistencya (Cronbach’s a) Test-retest reliabilityb ICC (95% CI) LOAb SDCb SEMb
MFI-total 0.92 0.80 (0.70e0.87) 22.21 to 24.34 14.68 5.30
MFI general fatigue 0.79 0.73 (0.61e0.82) 6.13 to 6.23 4.51 1.63
MFI physical fatigue 0.83 0.81 (0.71e0.87) 5.87 to 5.71 3.59 1.29
MFI reduced activity 0.88 0.74 (0.62e0.83) 6.79 to 7.96 5.31 1.92
MFI mental fatigue 0.86 0.65 (0.50e0.76) 6.95 to 7.91 6.25 2.25
MFI reduced motivation 0.74 0.79 (0.69e0.86) 5.63 to 5.68 3.67 1.32
95% CI, 95% Conﬁdence Interval; ICC, Intraclass correlation coefﬁcient; LOA, Limits of agreement; MFI, Multidimensional Fatigue Inventory; SDC, Smallest detectable change;
SEM, Standard error of measurement.
a N ¼ 153.
b N ¼ 77.
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a ranging from 0.74 (RM) to 0.92 (MFI-total).
Test-retest reliability was adequate for theMFI-total (ICC¼ 0.80,
95% CI¼ 0.70e0.87) andmost subscales (ICC ranged from 0.73 (95%
CI ¼ 0.61e0.82) (GF) to 0.81 (95% CI ¼ 0.71e0.87) (PF)). Test-retest
reliability was not adequate for the MF dimension (ICC ¼ 0.65, 95%
CI ¼ 0.50e0.76).
Measurement error, expressed by the SDC, was 15 points for the
MFI-total and ranged from 4 (PF and RM) to 7 points (MF) for all
subscales. Fig. 1 presents the Bland and Altman plots for the MFI-
total and all subscales. No systematic differences were found in
the late intervention group between the ﬁrst (t1) and second (t2)
administration.
3.2. Structural validity
The results of the PCA are presented in Table 3. Four factors were
extracted. The ﬁrst factor was interpreted as a combination of the
GF and PF dimensions and the other three factors as theMF, RM and
RA dimensions.Fig. 1. Graphic representation according to the Bland and Altman method for the MFI-total a
the limits of agreement (N ¼ 77).All 20 items had an unique loading of 0.40 on one of four
factors in the pattern matrix. Three items loaded on other factors
compared to the original MFI subscales. Item 3 (‘I feel very active’)
loaded on factor 3 (RM) instead of the RA subscale. Item 8 (‘Phys-
ically I can take on a lot’) and item 9 (‘I dread having to do things’)
loaded on factor 4 (RA) instead of the PF and RM subscale respec-
tively. The structure matrix shows a more complex model as 13
items loaded 0.40 across different factors. The maximum loading
for most items was consistent between the pattern- and the
structure matrix. Item 3 (‘I feel very active’) loaded in the pattern
matrix on factor 3 (RM) and had its maximum loading in the
structure matrix on factor 4 (RA).
The factor correlation matrix shows moderate correlations
between factor 1 (GF/PF) and factor 2 (MF) (r ¼ 0.35), between
factor 1 (GF/PF) and factor 4 (RA) (r ¼ 0.44), and between factor 3
(RM) and factor 4 (RA) (r ¼ 0.38).
3.2.1. Floor and ceiling effects
No ﬂoor or ceiling effects were found for the MFI-total and the
GF and RM subscales. TheMF subscale showed a ﬂoor effect (18.30%nd all subscales. Bold lines represent the mean difference score, dotted lines represent
Table 3
Principal component analysis, loadings in pattern- and structure matrixa,b and factor correlation matrix (N ¼ 153).
Factor 1 GF/PF Factor 2 MF Factor 3 RM Factor 4 RA
MFI general fatigue
I feel ﬁt (item 1) 0.78 (0.82) 0.11(0.23) 0.28 (0.42) 0.07 (0.48)
I feel tired (item 5) 0.68 (0.73) 0.14 (0.35) 0.32(0.13) 0.12 (0.35)
I feel rested (item 12) 0.71 (0.67) 0.20 (0.36) 0.18(0.08) 0.17(0.13)
I tired easily (item 16) 0.73 (0.79) 0.03 (0.30) 0.12(0.07) 0.14 (0.43)
MFI physical fatigue
Physically I feel I am in an excellent condition (item 20) 0.71 (0.76) 0.04 (0.33) 0.28 (0.40) 0.03(0.40)
Physically I feel I am in a bad condition (item 14) 0.73 (0.78) 0.00 (0.30) 0.10 (0.27) 0.08 (0.45)
Physically I can take on a lot (item 8) 0.35 (0.56) 0.11(0.19) 0.27 (0.48) 0.45 (0.67)
Physically I feel only able to do a little (item 2) 0.53 (0.71) 0.02(0.30) 0.17 (0.40) 0.35 (0.64)
MFI reduced activity
I think I do very little in a day (item 10) 0.01 (0.42) 0.07 (0.32) 0.16(0.20) 0.94 (0.90)
I think I do a lot in a day (item 6) 0.09(0.31) 0.04(0.21) 0.12 (0.43) 0.87 (0.87)
I get little done (item 17) 0.07 (0.48) 0.17 (0.43) 0.01(0.33) 0.80 (0.88)
I feel very active (item 3) 0.37 (0.58) 0.07(0.24) 0.42 (0.61) 0.36 (0.66)
MFI mental fatigue
When I am doing something, I can keep my thoughts on it (item 7) 0.01(0.30) 0.70 (0.74) 0.03(0.16) 0.17 (0.36)
I can concentrate well (item 11) 0.01 (0.34) 0.84 (0.87) 0.08 (0.25) 0.04 (0.32)
My thoughts easily wander (item 19) 0.01 (0.30) 0.81 (0.82) 0.10 (0.24) 0.02(0.26)
It takes a lot of effort to concentrate on things (item 13) 0.08 (0.34) 0.86 (0.86) 0.02 (0.15) 0.10(0.20)
MFI reduced motivation
I have a lot of plans (item 15) 0.08(0.17) 0.21 (0.35) 0.71 (0.78) 0.12 (0.41)
I feel like doing all sorts of nice things (item 4) 0.08 (0.23) 0.09 (0.24) 0.83 (0.83) 0.08(0.30)
I dread having to do things (item 9) 0.24 (0.48) 0.11 (0.33) 0.02 (0.25) 0.45 (0.60)
I don’t feel like doing anything (item 18) 0.02(0.31) 0.36 (0.52) 0.45 (0.62) 0.29 (0.55)
Eigenvalue 5.90 4.40 3.44 5.80
Kaiser-Meyer-Olkin (Barlett’s Test of Sphericity) 0.88 (p < 0.001)
Factor correlation matrixc
Factor 1 GF/PF e 0.35 0.18 0.44
Factor 2 MF 0.35 e 0.18 0.29
Factor 3 RM 0.18 0.18 e 0.38
Factor 4 RA 0.44 0.29 0.38 e
GF, General fatigue; MF, Mental fatigue; MFI, Multidimensional Fatigue Inventory; PF, Physical fatigue; RA, Reduced activity; RM, Reduced motivation.
a Loadings 0.40 are presented in bold.
b The ﬁgures in parentheses indicate loadings in the structure matrix.
c Expressed as Pearson r.
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found for the PF and RA subscales as respectively 16.30% and 15.70%
of patients achieved the highest possible score.
4. Discussion
To our knowledge, this study is the ﬁrst that investigated reli-
ability, structural validity, and ﬂoor and ceiling effects of the MFI in
patientswithPD. Thepresent study shows that theMFI-total and the
GF, PF, RA, andRM subscales have adequate internal consistency and
test-retest reliability. However, it is unclear whether measurement
errorwas adequate.Measurement error can be considered adequate
if the SDC is smaller than the minimal important change (MIC) or if
the MIC is outside the limits of agreement [19]. Unfortunately, no
results are known on anchor-based values for the MIC of the MFI in
patients with PD. Two studies [22,23] that investigated the MIC in
patients with systemic lupus erythematosus and rheumatoid
arthritis foundMIC values ranging from 12 [22] to 14 points [23] for
the MFI-total. One study [24] investigated the MIC for all MFI
subscales in patients with cancer and proposed a MIC of two points
for all subscales [24]. This suggests that the measurement error
found in our studymaynot be adequate and that theMFImaynot be
responsive to detect changes considered important by patients.
However, studies that use anchor-based methods to investigate the
MIC of the MFI in patients with PD are needed to conﬁrm whether
measurement error is adequate or not.
The SEM and SDC have been suggested as distribution-based
MIC values. However, distribution-based methods are mostapplicable when the estimation of a clinically meaningful change
does not rely on the estimate needing to be minimal [25]. The SDC
provides supportive informationwhether change scores on the MFI
exceed measurement error.
Principal component analysis failed to fully replicate the original
ﬁve-factor model. However, the found four-factor model,
combining most items of the GF and PF dimensions in one factor, is
in linewith two other studies that investigated structural validity of
the MFI in patients with cancer [26,27]. In addition, in the original
paper Smets and colleagues [8] found a four-factor model with
a combined GF and PF subscale that was equally acceptable as the
postulated ﬁve-factor model. The developers decided to retain the
ﬁve-factor model and concluded that if future research turns out
that using both the GF and PF subscale does not provide additional
information these two subscales may be combined [8].
Combining the GF and PF subscale poses a problem in calcu-
lating a global score for fatigue. The GF subscale has been proposed
as a short assessment for fatigue [8] and may be considered as
a global score for fatigue instead of the total summed score (MFI-
total) of all 20 items [3,28]. However, acknowledging the four-factor
model, this global score (GF) may reﬂect mainly physical aspects of
fatigue and may therefore not be valid to represent all dimensions
of fatigue measured with the MFI. Although PCA showed four
distinct factors, the interrelatedness of these factors may allow the
use of a total summed score of all 20 items to obtain a more valid
global indication of fatigue.
The factor correlation matrix showed moderate correlations
between most extracted factors, conﬁrming the complex
R.G. Elbers et al. / Parkinsonism and Related Disorders 18 (2012) 532e536536interrelatedness between different aspects of fatigue. Research,
focused on physiological and clinical aspects contributing to
peripheral and central fatigue [9] may be helpful to deﬁne concepts
and dimensions of fatigue more clearly. As both fatigue and most
clinical aspects contributing to fatigue ﬂuctuate over time and
show circadian rhythms, associations between these factors may be
more accurately studied by using longitudinal studies with inten-
sive, repeated measures in time [29].
Three items that loaded in the pattern matrix on other factors
compared to the original MFI subscales suggested a misﬁt of items.
However, taking the structure matrix and factor correlations
between factor 1 (GF/PF), factor 3 (RM) and factor 4 (RA) into
account, it is difﬁcult to assign these items uniquely to one factor.
With that, we decided not to consider these differences in factor-
loadings as misﬁts.
The found ﬂoor effect for the MF subscale and the ceiling effects
for the PF and RA subscales should be considered when evaluating
one of these aspects of fatigue. Furthermore, these results suggest
that mental fatigue and physical fatigue are two different aspects of
fatigue and further conﬁrm previous ﬁndings that mental fatigue
and physical fatigue are different symptoms in PD [29,30].
There are some study limitations that should be acknowledged.
First, we combined results from the Dutch and English language
version of the MFI. This may have resulted in cross-cultural differ-
ences within our sample. However, albeit in other patient pop-
ulations, both language versions were previously validated [8,17]
and we found no statistically signiﬁcant differences in fatigue
scores between Dutch and English speaking patients in our sample.
Second, we used PCA to investigate structural validity in a relatively
small sample. Although the Kaiser-Meyer-Olkin statistic indicated
reliable factors, this method provides preliminary data of the
factorial structure of the MFI and these results should be conﬁrmed
in future studies using more robust statistical analyses such as Item
Response Theory methods.
In conclusion, the present study shows that the MFI is a reliable
and valid instrument to assess the multidimensional aspects of
fatigue in patients with PD. Our results indicate that the found four-
factor model, combining the GF and PF dimensions into one
subscale, more validly measures the different aspects of fatigue
compared to the originally proposed ﬁve dimensions of the MFI.
However this model as well as the construct of underlying dimen-
sions of fatigue has to be conﬁrmed in future studies. We recom-
mend the use of the original version of the MFI to obtain a global
indication of fatigue by calculating a total summed score of all 20
items. Clinicians and researchers interested in assessing speciﬁc
aspects of fatigue should consider interpreting the GF and PF
dimensions as one subscale measuring physical aspects of fatigue.
Furthermore, a comprehensive evaluation of fatigue should be
accompanied by the assessment of clinically related factors such as
mood and sleep. To establish whether the MFI can detect mean-
ingful changes in clinical practice and research, studies on anchor-
based responsiveness and the MIC are needed in patients with PD.
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